SITE MAP
-
Terumo Medical Corporation | Home
-
About Terumo Corporation
-
Who We Are
-
Terumo Group at a Glance
-
Terumo Group Identity
-
History
-
Terumo's Purpose
-
Our Commitment to EHS
-
Locations
-
Ethics and Compliance
-
About
-
Terumo Interventional Systems
-
Terumo Medical Products
-
Pharmaceutical Solutions Division
-
Terumo Health Outcomes
-
Products List
-
Solutions
-
Research
-
Careers
-
New Account Application
-
Product Certification
-
Urgent: Medical Device Product Recall Notice
-
Product Notices
-
Unique Device Identifier FAQs
-
UDI GS1
-
Terms of Sale and Returns
-
Supplier Information
-
Support
-
Terumo Announces GMP Certification Has Been Awarded for the Manufacturing and Filling of Premixed Intravenous Solutions from the FDA (U.S.A.)
-
Terumo Announces European Launch of Biosimilar Using Terumo’s PLAJEX™ Pre-fillable Syringes
-
Terumo Announces Global Expansion into Canadian Market - Opens 58,000 square foot facility in Vaughan, Ontario
-
Novel Intrasaccular Aneurysm Treatment Device Receives FDA PMA Approval
-
Terumo Establishes New Group Identity Institutes "Core Values" to be Shared by All Associates
-
Terumo Enhances Coronary Interventional Product Portfolio By Securing Exclusive Global Rights to Orchestra BioMed’s Virtue® Sirolimus-Eluting Balloon (SEB) through Global Strategic Partnership
-
Terumo and Kikuna Memorial Hospital to Launch AI-tech Research to Improve PCI Procedure
-
Terumo Acquires Aortica Corporation
-
Terumo Establishes "Terumo Group Human Rights Policy"
-
Terumo Supports Gender Diversity and a Culture of Inclusion and Belonging
-
Terumo’s PLAJEXᵀᴹ Provides a Solution for a New Osteoporosis Treatment Developed and Manufactured on Contract
-
Terumo Responds to the Novel Coronavirus Outbreak in China
-
Terumo Announces Change of Executive Officers
-
Terumo Statement Regarding Production (COVID-19)
-
Terumo Interventional Systems Statement Regarding Production (COVID-19)
-
Terumo Statement on COVID-19
-
Terumo BCT and Marker Therapeutics Received the First Device FDA Emergency Use Authorization (EUA) to Treat Acute Respiratory Failure in COVID-19 Patients
-
Terumo Donates USD 2.4 Million in Cash and Products to Support COVID-19 Pandemic Relief Efforts Worldwide
-
Terumo Announces Receiving European Medicines Agency GMP Certification for the Manufacturing and Filling of Biologics in PLAJEX™ Polymer Pre-fillable Syringes at Yamaguchi Subsidiary’s Plant
-
Terumo Integrates Two R & D Facilities in Silicon Valley to Accelerate Development of Innovative Medical Devices
-
Vascutek and Bolton Medical Merge as ‘Terumo Aortic’
-
Terumo Appoints its U.S.-based Subsidiary's Associate as the Fifth Terumo Fellow
-
Terumo Announces Shipping Delays for Products from Ashitaka Factory
-
Terumo Acquires China-based Essen Technology To Enter Drug-eluting Stent Market in China
-
Terumo Pharmaceutical Solutions wins Asia-Pacific Industry Award
-
Terumo Acquires Quirem Medical to Enhance its Interventional Oncology Field
-
Terumo Statement Regarding Media Reports on Japanese Government's Subsidies Project
-
Terumo’s PLAJEX Enters US Markets by Receiving GMP Certification from FDA to Manufacture Biosimilar Hulio
-
Terumo North America Brings Intelligent Enterprise to Life During Worldwide Pandemic
-
Terumo Pharmaceutical Solutions wins Asia-Pacific Industry Award
-
Terumo Creates Global Group Music
-
Terumo Donates $40,000 to Support American Red Cross California Wildfires Relief Efforts
-
Terumo Announces Commercial Launch of the WEB™ in Japan
-
Terumo Enters 100th Anniversary Year
-
Terumo to Establish 'DX Promotion Department' for Accelerating Group-wide Digital Transformation
-
Terumo Announces Change of Directors and Executive Officers
-
Terumo Revises its Full-Year Financial Guidance for FY2020
-
Terumo Signs a Definitive Agreement to Acquire All Assets of Health Outcomes Sciences, Inc.
-
Terumo Donates Additional USD 1 Million to Support the COVID-19 Solidarity Response Fund for WHO - Contributions will Help Bolster Vaccine Equity
-
Terumo Introduces New AZUR™ Vascular Plug and PG Pro™ Peripheral Microcatheter Embolization System
-
Terumo Celebrates 100th Anniversary of Contributing to Society Through Healthcare
-
Terumo Medical Corporation Applauds ACC/AHA/SCAI Decision to Designate Radial Access Class 1, Level of Evidence A
-
Corazon and Terumo Sign Collaboration and Co-Marketing Agreement
-
Terumo Launches New ‘Terumo Medical Care Solutions’ Brand
-
Terumo Pharmaceutical Solutions offers pre-fillable syringe solutions for demanding low dose applications such as ophthalmic
-
Terumo Unveils “Terumo’s Purpose” to Enhance Joint Value Creation with Diverse Stakeholders
-
New Randomized Controlled Study Published in JAMA Demonstrates the Value of Clinical Decision Support Tools in Preventing Acute Kidney Injury in Patients Undergoing Coronary Angiography
-
Terumo Announces Study Results Underscoring Safety and Efficacy of Radial to Peripheral (R2P) Interventions in Treatment of Complex Lower Extremity Peripheral Artery Disease (PAD)
-
Terumo Prospective Registry Reinforces Safety, Efficacy and Efficiency of Radial Access in Visceral Interventions (R.A.V.I.) in Embolization Procedures
-
Prospective, Multi-Center, Single-Arm Study Demonstrates Effectiveness of Terumo Medical Corporation’s Cross-Seal™ Suture-Mediated Vascular Closure Device (VCD) System
-
Terumo Group’s Targets for Greenhouse Gas Reduction Approved by the SBT Initiative as 1.5°C Aligned
-
Terumo Medical Corporation’s New AZUR HydroPack™ Peripheral Coil System Provides a Soft-Packing, Long-Lasting Solution to Embolotherapy
-
Terumo Medical Corporation Breaks Ground on New Manufacturing Site at Its Puerto Rico Location
-
Terumo Medical Corporation Announces Launch and Commercial Availability of Its Peripheral R2P Navicross Support Catheter
-
News
-
SIR 2024
-
SCAI Fall Fellows
-
ISET
-
Events
-
News and Events
-
Order Tracking
-
Search Results
-
Site Map
-
Privacy Policy
-
Supplier Terms and Conditions
-
404 Page not found
-
500 Internal server error